Thanks for not posting RX weeklies

[Anonymous]

Really, that's risky. I won't want a state Attorney General after my ass.

Sissy

 

[Anonymous]

MSL Here:

We already saw in AVIATOR that 8 weeks is not long enough with Viekira. Next Gen is looking at shorter duration of therapy.

Aviator at 8 weeks showed 88% cure rate in genotype 1 treatment naive patients using Viekira + RBV. What was the SVR rate in Genotype 1b?

 

[Anonymous]

SVR is 10% I'm an insider in Chicago
Me and my partner are bean counters

 

[Anonymous]

Numbers will be great this week following our new data release!! Sales Tip for the Day: "Delivery of your V Pak value statement should take no more than 15 to 20 seconds — generally less." Good Selling! Louie Louie!! BFF!

 

[Anonymous]

Selling message from Lootzie to his underperforming sales force! "When it is obvious that the goals cannot be reached, don't adjust the goals, adjust the action steps." Now get out there and SELL!!!

 

[Anonymous]

Aviator at 8 weeks showed 88% cure rate in genotype 1 treatment naive patients using Viekira + RBV. What was the SVR rate in Genotype 1b?

MSL Here:

In the AVIATOR 8 week arm there were 24 GT1b patients (30%).

SVR12 was 96% (23/24). All are treatment naive and with RBV. We did not have a treatment exoerienced 8 week arm.

 

[Anonymous]

MSL Here:

In the AVIATOR 8 week arm there were 24 GT1b patients (30%).

SVR12 was 96% (23/24). All are treatment naive and with RBV. We did not have a treatment exoerienced 8 week arm.

So what you're saying is that as long as we use RBV, we're just as good as Harvoni without it...again. Very exciting.

 

[Anonymous]

"I'm Just saying" Dr Seuss is watching you "Bro"

 

[Anonymous]

Numbers will be great this week following our new data release!! Sales Tip for the Day: "Delivery of your V Pak value statement should take no more than 15 to 20 seconds — generally less." Good Selling! Louie Louie!! BFF!

Keep the sales momentum going!! Yahoo!! "According to data from Symphony Health and Bloomberg, AbbVie saw an 8.8% increase in total prescription volumes for its hep C drug Viekira Pak for the week ended June 19th. Total prescription volumes for Gilead Sciences' (NASDAQ:GILD) Harvoni and Sovaldi declined 5% and 10.5%, respectively."

 

[Anonymous]

I Love Loots and Haas and Ricky

 

[Anonymous]

Keep the sales momentum going!! Yahoo!! "According to data from Symphony Health and Bloomberg, AbbVie saw an 8.8% increase in total prescription volumes for its hep C drug Viekira Pak for the week ended June 19th. Total prescription volumes for Gilead Sciences' (NASDAQ:GILD) Harvoni and Sovaldi declined 5% and 10.5%, respectively."

What is our HCV 2q15 US & global market share targets?

 

[Anonymous]

What is our HCV 2q15 US & global market share targets?

3Q targets: US => 23.5%; global => 36%

 

[Anonymous]

3Q targets: US => 23.5%; global => 36%

LOL

 

[Anonymous]

Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Harvoni®, the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C

– Harvoni Achieved Cure Rates (SVR12) of 100 Percent in Japanese Phase 3 Study –

http://www.gilead.com/news/press-re...e-treatment-of-genotype-1-chronic-hepatitis-c

 

[Anonymous]

Re: Thanks for not posting RX Twinkies

Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Harvoni®, the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C

– Harvoni Achieved Cure Rates (SVR12) of 100 Percent in Japanese Phase 3 Study –

http://www.gilead.com/news/press-re...e-treatment-of-genotype-1-chronic-hepatitis-c

3Q targets: US => 2.5%; global => 2%
But experts agree that Thukral's initial stab at his summary section wasn't bad, but there was plenty of room for improvement. They gave him the following tip to focus on in his revision: Adopt a conversational tone in posting these strange studies.

 

[Anonymous]

Flootsie + Haaasie will begin posting their weekly BMs that they make together...in the big-boy toilet!

 

[Anonymous]

hopper your birthplace ?